Evidence map›Paper›PMID 32383089›Full record

ArticleEndocrine2020

Characterization of agonist-dependent somatostatin receptor subtype 2 trafficking in neuroendocrine cells.

Walaa Alshafie, Yingzhou Edward Pan, Hans-Jürgen Kreienkamp, Thomas Stroh

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Walaa AlshafieDepartment of Neurology and Neurosurgery, McGill University, and the Montreal Neurological Institute, Montreal, QC, Canada. walaa.alshafie@mail.mcgill.ca.
Yingzhou Edward PanDepartment of Neurology and Neurosurgery, McGill University, and the Montreal Neurological Institute, Montreal, QC, Canada.
Hans-Jürgen KreienkampInstitute for Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Thomas StrohDepartment of Neurology and Neurosurgery, McGill University, and the Montreal Neurological Institute, Montreal, QC, Canada. thomas.stroh@mcgill.ca.ORCID http://orcid.org/0000-0002-7220-0189
Montreal Neurological Institute and Hospital · CAUniversität Hamburg · DE

Funding

CIHR MOP-102713
6 · The paper itself

Abstract

backgroundSomatostatin (SOM) receptor subtype 2 (SSTR2) is the major receptor subtype mediating SOM effects throughout the neuraxis. We previously demonstrated that the non-selective agonist [D-Trp METHODS AND

resultsIn this study, we knocked-out SSTR5 in AtT20 cells endogenously expressing both SSTR2 and SSTR5 and used immuno-labeling and confocal microscopy to investigate the effect of SSTR5 on regulation of SSTR2 trafficking. Our results indicate that unlike [D-Trp

conclusionOur results indicate that the biased agonistic property of L-779,976 protects against SSTR2 surface depletion by rapidly initiating SSTR2 recycling while SSTR5 does not regulate L-779-976-dependent SSTR2 trafficking.

Indexed as

Neuroendocrine CellsReceptors, SomatostatinOctreotideSomatostatinOctreotideReceptors, SomatostatinSomatostatinIntracellular traffickingRecyclingSomatostatinSSTR2SSTR5

Identifiers

PMID32383089
OpenAlexW3022586976

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.